1M6MYTD1R5LMAX
Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 10,40 € (+194,62%). Mediana wynosi 10,40 € (+194,62%).
| Kupuj |
0 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
Zivo Bioscience switches trading to OTCID platform
Zivo Bioscience has transferred its common shares to the OTCID marketplace and has been traded there since Monday. The company, with a market capitalization of $15.21 million, recorded revenue growth of 165% over the past twelve months but remains unprofitable. The stock has fallen 78% year over year and is currently trading at $3.80; existing shareholders keep their holdings. Zivo will continue to provide corporate and financial information via the OTC Markets disclosure page to ensure transparency and market presence. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 0 | 100,00% |
| Zysk brutto | 0 | 100,00% |
| Zysk netto | -449,04 tys. | 67,73% |
| EBITDA | -445,98 tys. | 67,81% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 13,82 mln € |
Liczba akcji | 3,89 mln |
Maksimum/minimum z 52 tygodni | 15,17 € - 0,96 € |
| Dywidendy | Nie |
Beta | 0,11 |
C/Z (PE Ratio) | -2,93 |
PEG (PEG Ratio) | -0,05 |
C/WK (PB Ratio) | -5,03 |
C/S (PS Ratio) | 242,94 |
Profil spółki
| Nazwa | Zivo Bioscience |
| CEO | John Bernard Payne |
| Pracownicy | 7 |
